Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients

American Journal of Drug and Alcohol Abuse

Volumn 35, Issue 5, 2009, Pages 311-315

  Al Ghananeem, Abeer M ^a   Herman, Barbara H ^b   Abbassi, Maggie ^a   Yu, Elmer ^c   Miotto, Karen ^d   O'Brien, Charles P ^c   Ling, Walter ^d   Montgomery, Ann ^b   Walsh, Robert ^b  

^a University of Kentucky   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trial; Lofexidine; Oral delivery; Pharmacokinetics; Urine

Indexed keywords

BRITLOFEX; LOFEXIDINE; MORPHINE SULFATE; OPIATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; OPIATE ADDICTION; STEADY STATE; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CLONIDINE; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PILOT PROJECTS; TANDEM MASS SPECTROMETRY;

EID: 77649164433     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990903060135     Document Type: Article

References (17)

1. HallW, Darke S. Trends in opiate overdose deaths in Australia 1979-1995. Drug Alcohol Depend 1998; 52:71-77. (Pubitemid 28448705)
2. Smyth B, Fan J, Hser YI. Life expectancy and productivity loss among narcotics addicts thirty-three years after index treatment. J Addict Dis 2006; 25:37-47.
3. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001; 61:195-206.
4. Gowing LR, Farrell M, Ali RL, White JM. Alpha2 adrenergic agonists in opioid withdrawal. Addiction 2002; 97:49-58.
5. McCambridge J, Gossop M, Beswick T, Best D, Bearn J, Rees S, Strang J. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: Comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend 2007; 88:91-95.
6. Glasper A, Gossop M, deWet C, Reed L, Bearn J. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification. Pharmacology 2008; 81:92-96.
7. Bearn J, Gossop M, Strang J. Randomized double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend 1996; 43:87-91.
8. Carnwath T, Hardman J. Randomized double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend 1998; 50:251-254.
9. Gold MS, Pottash AC, Sweeney DR, Extein I, Annitto WJ. Lofexidine blocks acute opiate withdrawal. NIDA Research Monograph 1982; 41:264-268.
10. Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoya I, Fischman MW, Collins J, McSherry F, Boardman K, Davies DK, O'Brien CP, LingW, Kleber H, Herman BH. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 2008; 97:158-168.
11. Midgley I, Chasseaud LF, Taylor T, Darragh A. The absorption and excretion of 14C-lofexidine hydrochloride in man. Arzneimittelforschung 1982; 32:972-975.
12. Midgley I, Fowkes AG, Chasseaud LF, Hawkins DR, Girkin R, Kesselring K. Biotransformation of lofexidine in humans. Xenobiotica 1983; 13:87-95.
13. Al-Ghananeem AM. Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. J Pharm Sci 2008; 98:319-326.
14. Yu E, Miotto K, Akerele E, O'Brien CP, LingW, Kleber H, FischmanMW, Elkashef A, Herman BH, Al-Ghananeem AM. Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. The American Journal of Drug and Alcohol Abuse 2008; 34:606-611.
15. Davies DS, Wing AM, Reid JL, Neill DM, Tippett P, Dollery CT. Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine. Clin Pharmacol Ther 1977; 21:593-601.
16. MacGregor TR, Relihan GL, Keirns JJ. Pharmacokinetics of oral sustained release clonidine in humans. Arzneimittelforschung 1985; 35:440-446.
17. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116:496-526.